Welcome to our dedicated page for Insight Molecular Diagnostics SEC filings (Ticker: IMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Insight Molecular Diagnostics Inc. (IMDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a California-incorporated public company listed on Nasdaq, Insight Molecular Diagnostics files current and periodic reports that describe its financial condition, governance decisions, and key developments in its precision diagnostics business.
Through forms such as 8-K, investors can review announcements related to executive compensation changes, stock option grants under the company’s equity incentive plan, amendments to employment agreements, and other material events. Earnings-related 8-K filings furnish press releases that summarize quarterly financial results and business updates, including progress on the GraftAssure dd-cfDNA transplant testing platform.
In addition to current reports, users can locate annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy materials that address governance matters and executive compensation. These filings provide context on how Insight Molecular Diagnostics manages its transplant-focused diagnostics programs, quality and regulatory activities, and broader corporate strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major topics without reading every page. Real-time updates from EDGAR ensure that new IMDX filings, including any future registration statements or insider transaction reports on Form 4, are added as they become available. This page is a central resource for analyzing the regulatory record of Insight Molecular Diagnostics and its dd-cfDNA-based diagnostics business.
Insight Molecular Diagnostics Inc. reported new equity awards and a contract change for key executives. On September 28, 2025, the board granted stock options under the Amended and Restated 2018 Equity Incentive Plan to several leaders. Josh Riggs, President and CEO, received options to purchase 400,000 shares of common stock. Andrea James, CFO, and Dr. Ekkehard Schütz, Chief Science Officer, each received options for 235,000 shares, and James Liu, Vice President Accounting, Controller, Treasurer and Principal Accounting Officer, received options for 18,000 shares.
All options have an exercise price of $3.33 per share and vest over three years, with one-third vesting on the first anniversary and the remainder vesting in equal monthly installments over the following two years, subject to continued service. On September 29, 2025, the company also amended Dr. Schütz’s employment agreement so that his term continues until it is terminated in accordance with that agreement, rather than ending on a fixed four-year term.
Insight Molecular Diagnostics Inc. insider report: The company's Chief Financial Officer was granted an option to purchase 235,000 shares of common stock with an exercise price of $3.33 per share. The option was granted on 09/28/2025 and expires on 09/28/2035. Following the grant the reporting person beneficially owns 235,000 underlying shares, held directly. The option vests with 33 1/3% becoming exercisable after one year of continuous service from the grant date and the remaining balance vesting in 24 equal monthly installments thereafter, subject to continued service.
Insight Molecular Diagnostics reporting person Josh Riggs, who is listed as CEO and President and a director, acquired an option to purchase 400,000 shares of common stock on 09/28/2025. The option has an exercise price of $3.33 per share and an expiration date of 09/28/2035. The filing shows the reporting person directly beneficially owns the 400,000 option shares following the transaction. Vesting: 33 1/3% becomes exercisable after one year of continuous service from the grant date, with the remainder vesting in 24 equal monthly installments thereafter, subject to continued service. The Form 4 is signed by Josh Riggs on 09/30/2025.
Insight Molecular Diagnostics Inc. reported that its Board of Directors and Compensation Committee approved increases to the annual base salaries of two senior executives. Effective September 15, 2025, the annual base salary of President and Chief Executive Officer Joshua Riggs rose from $420,000 to $520,000, and the annual base salary of Chief Financial Officer Andrea James increased from $341,250 to $441,250. These changes reflect updated compensation levels for the company’s top leadership.